Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[89Zr]Zr-Df-Crefmirlimab
- Development stage
- Phase 2
- Lead developer
- ImaginAb
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
[89Zr]Zr-Df-Crefmirlimab is a radiopharmaceutical imaging agent designed for use in Positron Emission Tomography (PET) scans. It functions as a radioimmunoconjugate, comprising a minibody (an antibody fragment) that specifically targets and binds to the CD8 antigen expressed on CD8+ T cells. This minibody is conjugated to the chelator desferrioxamine (Df), which is labeled with the radioisotope Zirconium-89 ([89Zr]). The agent is utilized to visualize and quantify CD8+ T cells in the body, providing crucial information about immune responses in various conditions, including cancer and autoimmune diseases. It serves as a diagnostic tool rather than a therapeutic drug.
- Other names
- CD8 T cell I/O imaging agentCD8 T Cell imaging agentCD-8 T Cell imaging agentCD 8 T Cell imaging agentCD8-ImmunoPET minibody - ImaginAb Inc.CD-8-ImmunoPET minibody - ImaginAb Inc.CD 8-ImmunoPET minibody - ImaginAb Inc.Minibody CD8 T Cell imaging agent
02
Targets
CD8A (CD8 alpha/beta Coreceptor)
Beyond the preview
Go deeper on [89Zr]Zr-Df-Crefmirlimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [89Zr]Zr-Df-Crefmirlimab.